Amgen Inc’s Lumakras tablet lowered the risk of illness progression in patients with superior lung cancer by 34% compared with chemotherapy in a clinical trial, the company mentioned on Sunday. Read a few of the highlights of Georgia Health News’ …
Amgen Inc’s Lumakras tablet lowered the risk of illness progression in patients with superior lung cancer by 34% compared with chemotherapy in a clinical trial, the company mentioned on Sunday. Read a few of the highlights of Georgia Health News’ …